1
Return

From RAS inhibitor resistance to rational combination strategies

delete2026-08-11
delete0
PRE
AI
P
Paula Lynch
T
Teresa Macarulla
G
Grainne M. O’Kane *
DOI：10.1038/s41591-026-04529-wdelete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
As new drugs that target mutant RAS redefine the therapeutic landscape in the treatment of pancreatic cancer, understanding and intercepting resistance is critical; a new study reveals mechanisms of acquired genetic resistance to daraxonrasib, highlighting putative combination approaches.

Journal

Nature Medicine cover
Nature Medicine
IF:
50
Papers:
1.4W
Citations:
13.4W

Organization

U
university college dublin
Scholars:
2.5W
Papers: 2.2W
Citations: 22
I
idibaps
Scholars:
7.8K
Papers: 5.8K
Citations: 25
Cited Papers

Cited Papers

Citing Papers

Citing Papers